mirikizumab   Click here for help

GtoPdb Ligand ID: 9846

Synonyms: Antibody I [US9023358] | LY-3074828 | LY3074828 | mirikizumab-mrkz | Omvoh®
Approved drug Immunopharmacology Ligand
mirikizumab is an approved drug (Japan, EMA and FDA (2023))
Compound class: Antibody
Comment: Mirikizumab (LY-3074828) is a humanized monoclonal antibody against human IL-23A (IL-23p19) which is designed for the treatment of autoimmune diseases. It is one of the novel agents for immune-mediated inflammatory diseases discussed in Baker et al. (2018) [1]. The peptide sequences of mirikizumab heavy and light chains are 100% matches to sequences 9 and 10 of Antibody I that is claimed in patent US9023358 [2].
Classification Click here for help
Compound class Antibody
Approved drug? Yes (Japan, EMA and FDA (2023))
International Nonproprietary Names Click here for help
INN number INN
10657 mirikizumab
Synonyms Click here for help
Antibody I [US9023358] | LY-3074828 | LY3074828 | mirikizumab-mrkz | Omvoh®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 767
Other databases
GtoPdb PubChem SID 363894140
Search PubMed clinical trials mirikizumab
Search PubMed titles mirikizumab
Search PubMed titles/abstracts mirikizumab